Evidence map›Paper›PMID 33253892›Full record

ArticleEuropean journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V2021

Synergistic activity of phage PEV20-ciprofloxacin combination powder formulation-A proof-of-principle study in a P. aeruginosa lung infection model.

Yu Lin, Diana Quan, Rachel Yoon Kyung Chang, Michael Y T Chow, Yuncheng Wang, Mengyu Li, Sandra Morales, Warwick J Britton, Elizabeth Kutter, Jian Li and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 73 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Multidrug-resistantFrontiers in microbiology · 2025
    Review
  12. Article
  13. Targeting neutrophil serine proteases in bronchiectasis.The European respiratory journal · 2025
    Review
  14. Article
  15. Review
  16. Article
  17. Viruses · 2024
    Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Yu LinAdvanced Drug Delivery Group, School of Pharmacy, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
Diana QuanCentenary Institute and Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
Rachel Yoon Kyung ChangAdvanced Drug Delivery Group, School of Pharmacy, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
Michael Y T ChowAdvanced Drug Delivery Group, School of Pharmacy, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
Yuncheng WangAdvanced Drug Delivery Group, School of Pharmacy, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
Mengyu LiAdvanced Drug Delivery Group, School of Pharmacy, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
Sandra MoralesPhage Consulting, Sydney, NSW, Australia.
Warwick J BrittonCentenary Institute and Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
Elizabeth KutterThe Evergreen State College, Olympia, WA, USA.
Jian LiMonash Biomedicine Discovery Institute, Department of Microbiology, Monash University, Clayton, Victoria, Australia.
Hak-Kim ChanAdvanced Drug Delivery Group, School of Pharmacy, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia. Electronic address: kim.chan@sydney.edu.au.
University of Sydney · AUCentenary Institute · AUMonash University · AUThe Evergreen State College · US

Funding

Harnessing bacteriophages as natural predators to combat the superbugs: a pulmonary drug delivery approachR33AI121627 · NIAID · UNIVERSITY OF SYDNEY · PI CHAN, KIM · 2018 to 2020
$598k
NIAID NIH HHS R33 AI121627
6 · The paper itself

Abstract

Combination treatment using bacteriophage and antibiotics is potentially an advanced approach to combatting antimicrobial-resistant bacterial infections. We have recently developed an inhalable powder by co-spray drying Pseudomonas phage PEV20 with ciprofloxacin. The purpose of this study was to assess the in vivo effect of the powder using a neutropenic mouse model of acute lung infection. The synergistic activity of PEV20 and ciprofloxacin was investigated by infecting mice with P. aeruginosa, then administering freshly spray-dried single PEV20 (10

Indexed as

Administration, InhalationAnimalsAnti-Bacterial AgentsBacterial LoadCiprofloxacinCombined Modality TherapyDry Powder InhalersFemaleHumansLungMicePhage TherapyPneumonia, BacterialPowdersProof of Concept StudyPseudomonas aeruginosaAnti-Bacterial AgentsCiprofloxacinPowdersAntibiotic aerosolsBacteriophage therapyCombination therapyDry powder inhalation (DPI)Inhaled phage therapyMouse lung infection modelPhage and antibiotic combination

Identifiers

PMID33253892
PMCPMC7855557
OpenAlexW3107162773

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.